AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, B-Cell, Marginal ZoneCentral Nervous System NeoplasmsLymphoma, FollicularLymphoma, T-CellBone NeoplasmsGerminal CenterProto-Oncogene Proteins c-bcl-6B-LymphocytesLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, ImmunoblasticCombined Modality TherapyBurkitt LymphomaAntibodies, Monoclonal, Murine-DerivedVincristineAntigens, CD79Mediastinal NeoplasmsMyelin and Lymphocyte-Associated Proteolipid ProteinsPrednisoneEpstein-Barr Virus InfectionsHodgkin DiseaseTranslocation, GeneticAntigens, CD20CyclophosphamideDoxorubicinLymphoma, Mantle-CellLymphoproliferative DisordersImmunophenotypingFatal OutcomeImmunohistochemistryLymphoma, T-Cell, CutaneousCARD Signaling Adaptor ProteinsImmunoglobulin Heavy ChainsChemotherapy-Induced Febrile NeutropeniaLymphoma, AIDS-RelatedB-Lymphocyte SubsetsAntineoplastic Combined Chemotherapy ProtocolsHerpesvirus 4, HumanLymphoma, Large-Cell, AnaplasticPrognosisTreatment OutcomeCell Line, TumorProto-Oncogene Proteins c-bcl-2Gene Expression Regulation, NeoplasticTumor Markers, BiologicalRemission InductionRetrospective StudiesGene Expression ProfilingPolymerase Chain ReactionDNA-Binding ProteinsLymphocyte ActivationImmunoglobulin MSpleenImmunoglobulin DMutationFlow CytometryGenes, ImmunoglobulinAntibodies, MonoclonalGene Rearrangement, B-LymphocyteAntigens, CD5Mice, Inbred C57BLLeukemia, Lymphocytic, Chronic, B-CellLymph NodesGene Rearrangement, B-Lymphocyte, Heavy ChainAntigens, CD19Lymphoma, Extranodal NK-T-CellImmunoglobulin Variable RegionSialic Acid Binding Ig-like Lectin 2Antigens, CDImmunoglobulinsB-Cell Activating FactorChromosomes, Human, Pair 14Antigens, CD40Cell DifferentiationGene RearrangementMice, Inbred BALB CMice, TransgenicLymphocyte CooperationAntigens, CD30Immunoglobulin GPrecursor Cells, B-LymphoidAntigens, Differentiation, B-LymphocyteChromosomes, Human, Pair 18Molecular Sequence DataLeukemia, B-CellSurvival AnalysisClone CellsB-Cell Activation Factor ReceptorLymphoid TissueImmunologic MemoryCells, CulturedReed-Sternberg CellsTumor Cells, CulturedCell LineAntibody FormationSignal TransductionMice, Knockout
FollicularDLBCLCentral nervous systemBurkittMantleDiagnosisLymphocytesTumorsPanniculitis-like T-cell lymMalignant lymphomaMarginalExtranodal lymphomasForms of lymphomaIndolentHodgkinSubtypesTumorHigh-grade B-cell lymLymphoplasmacytic lymphomaCD20ClinicalAggressive lymphomasCutaneous diffusePMBCLSubcutaneousHodgkin's LymphomaRituximabChemotherapyAutologousLymph nodesCases of lymphomaPatient'sLymphaticForm of extranodalCancersPeripheralLeukemiaSystemicImmune systemBone marrowTypeTesticularTherapiesTreatmentHighly aggressive
Follicular16
  • Other forms of PTL include testicular mantle cell lymphoma, extranodal marginal zone B cell lymphoma, extranodal NK/T-cell lymphoma, nasal type, peripheral T-cell lymphoma, activin receptor-like kinase-1-negative anaplastic large cell lymphoma, and pediatric-type follicular lymphoma. (wikipedia.org)
  • All forms of PTL except the pediatric-type follicular lymphoma are highly aggressive malignancies PT-DLBCL is no exception to this rule: it begins in a testis, often spreads to the contralateral (i.e. uninvolved) testis as well as to the central nervous system and other sites, and commonly recurs following its treatment. (wikipedia.org)
  • TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. , (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. (biospace.com)
  • Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243). (springer.com)
  • Participants with DLBCL transformed from follicular lymphoma (FL) or marginal zone lymphoma (MZL, including mucosa-associated lymphoid tissue [MALT] lymphomas), lymphoplasmacytic lymphoma (LPL), or nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) are eligible. (uci.edu)
  • SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta ® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (gilead.com)
  • The approval makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA Breakthrough Therapy Designation and a priority review, and marks the third approved indication for a Kite cell therapy. (gilead.com)
  • Once a follicular lymphoma patient's disease relapses, the duration of response to care shortens with each round of therapy," said Caron A. Jacobson, MD, MMSc, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School. (gilead.com)
  • Impressively, 91 percent of follicular lymphoma patients in the ZUMA-5 study responded to a single infusion of axicabtagene ciloleucel, including an estimated 74 percent of patients in a continued remission at 18 months, giving these patients much-needed hope and oncologists an important addition to the treatment armamentarium. (gilead.com)
  • Advancing CAR T therapies for patients across lymphomas remains a cornerstone of our cell therapy development program, and we are excited about the potential of Yescarta for patients with indolent follicular lymphoma. (gilead.com)
  • This is an important new treatment option for people with third-line relapsed or refractory follicular lymphoma," said Lee Greenberger, PhD, Chief Scientific Officer of The Leukemia & Lymphoma Society (LLS). (gilead.com)
  • Follicular lymphoma (FL) is a form of indolent non-Hodgkin lymphoma (iNHL) in which malignant tumors slowly grow but can become more aggressive over time. (gilead.com)
  • The therapy was approved for treating certain types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma). (pharmtech.com)
  • The BLA is supported by data from the pivotal phase 1 study ( TRANSCEND NHL 001 ) that assessed the safety, antitumor activity, and pharmacokinetics of liso-cel in 268 patients with relapsed or refractory large B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), high-grade lymphoma (HGL), primary mediastinal B-cell lymphoma (PMBCL), and Grade 3B follicular lymphoma (FL). (empr.com)
  • The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic therapy. (onclive.com)
  • liso-cel) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) following 2 or more lines of systemic therapy. (onclive.com)
DLBCL30
  • Primary testicular diffuse large B-cell lymphoma (PT-DLBCL), also termed testicular diffuse large B-cell lymphoma and diffuse large B-cell lymphoma of the testes, is a variant of the diffuse large B-cell lymphomas (DLBCL). (wikipedia.org)
  • DLBCL are a large and diverse group of B-cell malignancies with the great majority (-85%) being typed as diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). (wikipedia.org)
  • Other variants and subtypes of DLBCL may involve the testes by spreading to them from their primary sites of origin in other tissues. (wikipedia.org)
  • The B-cells in PT-DLBCL are malignant lymphocytes that normally function in the humoral immunity component of the adaptive immune system by secreting antibodies that, for example, bind to and neutralize invasive pathogens. (wikipedia.org)
  • While DLBCL may involve either type of B-cell, the various forms and subtypes of the DLBCL that involve activated B-cells are more aggressive and may require different therapies than those involving germinal center B-cells. (wikipedia.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma . (cancercenter.com)
  • The majority of non-Hodgkin lymphomas affect B cells, and this is true of DLBCL. (cancercenter.com)
  • DLBCL gets its name because the malignant B cells are larger than healthy B cells, and they are diffuse, meaning they don't clump together when seen under a microscope. (cancercenter.com)
  • While still rare, primary mediastinal B-cell lymphoma is the most common subtype of DLBCL. (cancercenter.com)
  • Like DLBCL, primary mediastinal B-cell lymphoma is a fast-growing tumor, but it tends to respond well to treatment. (cancercenter.com)
  • Doctors don't know exactly what causes DLBCL or other non-Hodgkin lymphomas. (cancercenter.com)
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP-the standard treatment regimen. (news-medical.net)
  • Of them, diffuse large B-cell lymphoma (DLBCL) is the most common Non-Hodgkins lymphoma and is highly aggressive and fast-growing. (news-medical.net)
  • A 51 year old male patient was diagnosed with primary central nervous system (CNS) non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), with approximately 50% of Ki-67 positive cells. (fortuneonline.org)
  • Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and the most common gastrointestinal lymphoma. (fujita-hu.ac.jp)
  • Methods: This retrospective study included 174 patients with primary gastric (n = 129) or intestinal (n = 45) DLBCL treated with rituximab-containing chemotherapy between 1995 and 2018. (fujita-hu.ac.jp)
  • Diffuse large B cell lymphoma (diffuse LBCL or DLBCL) is a cancer that affects white blood cells called B cell lymphocytes. (medicalnewstoday.com)
  • In DLBCL, abnormalities within the B cell lymphocytes mean the cells no longer develop and function as they should. (medicalnewstoday.com)
  • FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL). (biospace.com)
  • [ 4 ] Clinical outcomes differ by histologic subtype with 5-year overall survival rates ranging from 30% in DLBCL to 79% in marginal zone lymphoma. (medscape.com)
  • The DLBCL type of primary central nervous system lymphoma (PCNSL) is composed of immunoblasts or centroblasts that have a predilection for blood vessels and thus demonstrate a typical angiocentric growth pattern. (medscape.com)
  • The diffuse large B-cell lymphoma (DLBCL) accounts for the majority of cases. (intechopen.com)
  • Assess the safety and toxicity of atezolizumab in combination with immunogenic chemotherapy (gemcitabine plus oxaliplatin) with rituximab (R-GEMOX-ATEZO) in patients with relapsed or refractory (rel/ref) transformed diffuse large B-cell lymphoma (DLBCL), including determination of the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of R-GEMOX-ATEZO. (ucsd.edu)
  • 1] Most primary lymphomas of the bone are of the NHL type and of the diffuse large B-cell lymphoma (DLBCL) subtype. (medscape.com)
  • Participants must have histologically or cytologically confirmed diffuse large B-cell lymphoma (DLBCL), Ann Arbor Stage IIX (bulky), III or IV. (uci.edu)
  • Background: Tisagenlecleucel demonstrated a high rate of durable response in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the pivotal global phase 2 JULIET study. (elsevierpure.com)
  • Methods: JULIET (NCT02445248) is a single-arm, open-label, multicenter, phase 2 study involving adult patients with r/r DLBCL who either relapsed after or were ineligible for autologous stem cell transplant. (elsevierpure.com)
  • Outcomes for diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous hematopoietic cell transplantation (auto-HCT) have been historically poor. (wustl.edu)
  • This is the largest study to date to evaluate outcomes of DLBCL patients relapsing after auto-HCT. (wustl.edu)
Central nervous system4
  • Primary central nervous system lymphoma (PCNSL) has been known by many other names, including reticulum cell sarcoma, diffuse histiocytic lymphoma, and microglioma. (medscape.com)
  • Primary central nervous system lymphoma in children is usually of the diffuse large B-cell lymphoma type. (dana-farber.org)
  • Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
  • The therapy is not indicated for treating primary central nervous system lymphoma. (pharmtech.com)
Burkitt3
Mantle1
  • Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. (lu.se)
Diagnosis19
  • Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. (nih.gov)
  • Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. (nih.gov)
  • As cytomorphological appearance was consistent with anaplastic carcinoma in ultrasonography-guided aspiration biopsies of thyroid nodule and lymphadenopathy, immunohistochemical staining was performed for differential diagnosis of lymphoma. (endocrine-abstracts.org)
  • According to Revised European American Classification of Lymphoid Neoplasms, the diagnosis was diffuse large B-cell lymphoma. (endocrine-abstracts.org)
  • We introduce the case in order to emphasize that infiltration of diffuse large B-cell lymphoma should be recalled with instantaneous enlargement of nodules known to be benign previously, and when cytological specimen is uncertain, immunohistochemical staining should be performed for differential diagnosis. (endocrine-abstracts.org)
  • Immunohistochemistry staining tested positive for CD20 ( Figure 4 ), leading to a diagnosis of right atrial diffuse large B cell lymphoma, non-germinal center (activated) type. (frontiersin.org)
  • This confirmed the diagnosis of primary cardiac lymphoma (PCL). (frontiersin.org)
  • Since the clinical and neuroimaging presentation of PCNSL can be varied and the differential diagnostic possibilities are therefore large, no patient should be treated for PCNSL without definitive cytologic proof of diagnosis, either by vitrectomy, CSF sampling, or brain biopsy. (medscape.com)
  • The radiologic differential diagnosis was lymphoma, primary glial neoplasm or subacute infarct. (pathologyoutlines.com)
  • Primary diffuse large B-cell lymphoma of the central nervous system is a rare tumor that b y definition, arises exclusively in the CNS with no obvious lymphoma elsewhere at diagnosis. (pathologyoutlines.com)
  • However, nearly all tumors have a background of reactive T cells that may lead to an erroneous diagnosis of T cell lymphoma. (pathologyoutlines.com)
  • Learn more about childhood non-Hodgkin lymphoma , including diagnosis and treatment . (dana-farber.org)
  • A doctor will carry out several tests to confirm a non-Hodgkin's lymphoma diagnosis. (healthline.com)
  • A lymphoma diagnosis often includes imaging tests. (healthline.com)
  • Primary non-Hodgkin lymphoma (NHL) of bone can be a difficult to diagnosis without a high level of suspicion. (medscape.com)
  • 9] The radiologic differential diagnosis includes benign entities (reactive conditions, osteomyelitis) and malignant entities (Hodgkin lymphoma, sarcoma, neuroblastoma, metastatic disease). (medscape.com)
  • Diagnosis: Lymphoma Subjects with lymphoma must have progressed, had SD, or recurred after initial treatment regimens that include an anthracycline and an anti CD20 monoclonal antibody. (who.int)
  • Deep learning shows the capability of high-level computer-aided diagnosis in malignant lymphoma. (cdc.gov)
  • Automated Diagnosis of Lymphoma with Digital Pathology Images Using Deep Learning. (cdc.gov)
Lymphocytes13
  • The cancer starts in cells called lymphocytes, which are white blood cells that help the body fight off infections. (cancercenter.com)
  • White blood cells or lymphocytes are the soldiers of our immune system that patrol the body via the lymphatic system. (news-medical.net)
  • Lymphoma, a type of blood cancer, results from the uncontrolled proliferation of lymphocytes. (news-medical.net)
  • Diffuse LBCL is a type of cancer that affects white blood cells called lymphocytes. (medicalnewstoday.com)
  • There are two main types of lymphocytes: B cell lymphocytes (B cells) and T cell lymphocytes (T cells). (medicalnewstoday.com)
  • This examination showed a diffuse proliferation of large atypical lymphocytes exhibiting mitotic activity and apoptosis along with extensive areas of necrosis. (frontiersin.org)
  • Although the cells of origin are lymphocytes, PCNSL should be considered a brain tumor, because the therapeutic challenges resemble those of other brain tumors. (medscape.com)
  • The CAR-T cells are trained to attack only b-lymphocytes which are the cancer cells in lymphoma. (cancer.org)
  • So attacking the cancer cells in this case means attacking b lymphocytes only some of which are cancerous clones, some are healthy. (cancer.org)
  • The lymphatic system carries lymph, a colorless fluid containing white blood cells called lymphocytes. (cancer.net)
  • B lymphocytes are a type of white blood cell. (dermnetnz.org)
  • The Fc portion then recruits immune cells that destroy these lymphocytes. (dermnetnz.org)
  • The CARD11 gene provides instructions for making a protein involved in the function of immune system cells called lymphocytes, particularly certain types called T cells and B cells. (medlineplus.gov)
Tumors12
  • Malignant causes included primary or secondary cardiac tumors, lung cancer, mediastinal tumors, or lymphoma, which may obstruct or compress the superior vena cava. (frontiersin.org)
  • PCNSL occurs at an incidence of 0.47 per 100,000 person-years, accounting for 4%-6% of extranodal lymphomas and 4% of newly diagnosed CNS tumors. (medscape.com)
  • Primary brain lymphomas have scant cytoplasm, high grade nuclei and multiple nucleoli, but less pleomorphism than other high grade CNS tumors. (pathologyoutlines.com)
  • These can occur in lymph nodes or in sites such as the gastrointestinal tract or the inner eyelids, where these tumors are referred to as mucosa-associated lymphoid tissue (MALT) lymphomas. (dana-farber.org)
  • NYSE:NVS) said radioligand therapy Lutathera 177Lu-Dotatate showed a significant progression-free survival benefit in the Phase III NETTER-2 trial as first-line therapy for gastroenteropancreatic neuroendocrine tumors, meeting the study's primary endpoint. (biocentury.com)
  • Primary NHL of bone (primary bone lymphoma) is a rare condition, accounting for less than 1-2% of adult NHL and less than 7-10% primary bone tumors. (medscape.com)
  • Together, Gilead and Kite will accelerate studies of CAR-T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors, with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy. (pharmtech.com)
  • My research interests comprise cutaneous tumors with emphasis in lymphomas and melanoma. (mdanderson.org)
  • In lymphomas I have conducted studies in rare aggressive primary cutaneous tumors such as gamma/delta T cell lymphoma (expanding the description of the epidermotropic variant) as well as more indolent entities such as lymphomatoid papulosis (type D) and CD4-positive small to medium size T cell lymphoproliferative disorders. (mdanderson.org)
  • Primary malignant bone tumors are much less common than metastatic bone tumors, particularly in adults. (msdmanuals.com)
  • Malignant tumors may be primary or metastatic. (msdmanuals.com)
  • some are malignant primary tumors (eg, osteosarcoma. (msdmanuals.com)
Panniculitis-like T-cell lym1
Malignant lymphoma4
Marginal1
  • Cutaneous B-cell lymphoma includes follicle centre, marginal zone, and diffuse large B-cell lymphoma, which have all been reported to respond to intravenous rituximab. (dermnetnz.org)
Extranodal lymphomas1
  • On the other hand, Primary thyroid lymphoma (PTL) is a rare entity accounting for only about 1% to 5% of all thyroid malignancies and only 2% of extranodal lymphomas. (aku.edu)
Forms of lymphoma2
  • Lymphomas that begin in the testes, i.e. primary testicular lymphomas (PTL), are rare forms of lymphoma that represent 1-2% of all non-Hodgkins lymphomas and 5% of all testicular malignancies. (wikipedia.org)
  • Some forms of lymphoma increase LDH production. (healthline.com)
Indolent2
Hodgkin12
  • Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of malignancies of different biology and prognosis. (medscape.com)
  • Diffuse LBCL is a type of non-Hodgkin lymphoma (NHL) . (medicalnewstoday.com)
  • PCNSL is now known to be a form of extranodal, high-grade non-Hodgkin B-cell neoplasm, usually large cell or immunoblastic type. (medscape.com)
  • I have been diagnosed with High Grade (CD19, 20, 22 and Max 5 affected) Large B Cell Non Hodgkin Lymphoma (Dx Jan 16th 2017). (cancer.org)
  • Most non-Hodgkin lymphomas (NHL) in children are fast growing, aggressive cancers. (dana-farber.org)
  • Children and teens with rare childhood non-Hodgkin lymphoma are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Lymphoma Program in our Childhood Hematologic Malignancy Center . (dana-farber.org)
  • Non-Hodgkin lymphoma (NHL) is a cancer of the lymphatic system. (cancer.net)
  • The term non-Hodgkin lymphoma (NHL) encompasses a heterogeneous mix of lymphomas, which are either of a B- or T-cell phenotype and that meet the diagnostic criteria for one of the subtypes detailed in the 2008 World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. (medscape.com)
  • Anemia and/or elevated lactate dehydrogenase (LDH), alkaline phosphatase (ALP), erythrocyte sedimentation rates (ESRs), platelet counts, and calcium levels have been reported with primary non-Hodgkin lymphoma (NHL) of bone. (medscape.com)
  • Grossly the lesions of primary non-Hodgkin lymphoma (NHL) of bone are usually yellow-tan and fleshy in appearance. (medscape.com)
  • But sometimes non-Hodgkin lymphoma (NHL) develops in people who don't have any of the risk factors described below. (cancer.ca)
  • This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma. (pharmtech.com)
Subtypes1
Tumor12
  • Their article describes in detail various aspects of tumor biology, including molecular pathways, tumor microenvironment, clonal evolution (selective growth of particular cells) and cell of origin that can help identify potential mechanisms and predictive biomarkers of drug resistance. (news-medical.net)
  • However, the tumor microenvironment, comprising a milieu of immune factors, cells, and extracellular components, greatly influences how the tumor responds to the drug. (news-medical.net)
  • Drug-resistant and unresponsive lymphomas are known to harbor genetic variations that enable the tumor to evade the drug molecules, thereby making them tolerant towards R-CHOP treatment. (news-medical.net)
  • Several mechanisms lead to hypercalcemia in malignancy-direct osteolysis by metastatic disease or, more commonly, production of humoral factors by the primary tumor also known as humoral hypercalcemia of malignancy that accounts for about 80% of malignancy-related hypercalcemia. (hindawi.com)
  • Baseline transesophageal echocardiography with 3D reconstruction, showing a large tumor arising from the lateral wall of the right atrium (white arrows). (frontiersin.org)
  • Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (ucsd.edu)
  • Evaluate on-treatment changes in density of and proximity between immune cell subsets in the tumor microenvironment after immunogenic chemotherapy alone and R-GEMOX-ATEZO by multispectral immunofluorescence, including density of CD8+ cells and cytotoxic lymphocyte (CTL):regulatory T cell (Treg) ratio. (ucsd.edu)
  • Most types of cancer begin when healthy cells change and grow out of control, forming a mass called a tumor. (cancer.net)
  • Lymphoma begins when healthy cells in the lymphatic system change and grow out of control, which may form a tumor. (cancer.net)
  • Evaluation of a convolution neural network for baseline total tumor metabolic volume on [F]FDG PET in diffuse large B cell lymphoma. (cdc.gov)
  • Osteosarcoma is the most common malignant primary bone tumor (if one considers myeloma a marrow cell tumor and not a primary bone tumor) and is highly malignant. (msdmanuals.com)
  • Some factors such as individual treatment strategy, according to the histology of the primary tumor, plan of treatment strategies carried out in a multidisciplinary manner, risk-benefit of radiotherapy, assessment of the degree of spinal instability, improvement in communication and referral between specialists in oncology showed an increase in the survival of these patients. (bvsalud.org)
High-grade B-cell lym1
  • Ganapathi M, Lake DN, Griffiths AP: Periprosthetic high-grade B-cell lymphoma complicating an infected revision total hip arthroplasty. (karger.com)
Lymphoplasmacytic lymphoma1
  • BACKGROUND: Waldenström macroglobulinemia (WM) is a subset of lymphoplasmacytic lymphoma (LPL) with bone marrow (BM) involvement and an IgM monoclonal gammopathy of any level. (koreamed.org)
CD209
  • Diffuse large B-cell lymphoma cells showing CD20 involvement were seen in cytological specimens. (endocrine-abstracts.org)
  • While normal thyrocytes were detected in thyroid gland, atypical lymphoid cells showing diffuse infiltration in thyroid tissue were observed in the nodule, which were stained diffuse, strongly positive for CD20 and BcL and negative for CD45 RO. (endocrine-abstracts.org)
  • Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. (biospace.com)
  • Most primary CNS lymphomas are diffuse large B cell subtype, and are immunoreactive for CD20, CD79a and CD22, but negative for CD3. (pathologyoutlines.com)
  • It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. (ucsd.edu)
  • The drug candidate consists of autologous T-cells are engineered to express dual chimeric antigen receptors (CAR) that targets cells expressing CD19 and CD20. (pharmaceutical-technology.com)
  • The CD20 antigen is not found on stem cells or early pro- B cells so these can regenerate the B lymphocyte population. (dermnetnz.org)
  • Plasma cells are B cells that do not usually express the CD20 antigen, so they mostly survive. (dermnetnz.org)
  • Retreatment may or may not prove successful as lymphomas can lose CD20 expression and, with that, susceptibility to rituximab. (dermnetnz.org)
Clinical9
  • The National Cancer Institute's Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • They are classified as Hodgkins and Non-Hodgkins lymphomas on the basis of the cell of origin and clinical characteristics. (news-medical.net)
  • We compared giDLBCL cases and investigated the clinical utility of newly emerging indicators with an emphasis on programmed cell death ligand 1 (PD-L1) expression. (fujita-hu.ac.jp)
  • Regeneron is also initiating a broad Phase 3 development program to investigate odronextamab in earlier lines of therapy and other B-NHLs, representing one of the largest clinical programs in lymphoma. (biospace.com)
  • Work is going on to target only the cancerous b cells only but that technology is fraught with side effects and currently not approved outside of clinical trials. (cancer.org)
  • KITE-363 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. (pharmaceutical-technology.com)
  • The Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J.{Ref 1} In 1994, the Revised European-American Lymphoma (REAL) classification attempted to apply immunophenotypic and genetic features in identifying distinct clinicopathologic NHL entities. (medscape.com)
  • The 2015 Workshop on Immunodeficiency and Dysregulation, organized by the Society for Hematopathology (SH) and the European Association for Haematopathology (EAHP), brought together a large number of well-annotated cases from diverse clinical backgrounds and included 415 cases from 21 countries. (medscape.com)
  • 2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
Aggressive lymphomas2
  • This positive CHMP opinion is an important milestone that recognizes [liso-cel] as a differentiated cell therapy with the potential to address unmet needs for patients in the European Union with aggressive lymphomas who have limited treatment options," Anne Kerber, senior vice president of Cellular Therapy Development at Bristol Myers Squibb, stated in a press release. (onclive.com)
  • Immunodeficiency-related lymphoproliferative disorders (LPDs) form a heterogeneous group that ranges from self-limiting hyperplasias to aggressive lymphomas. (medscape.com)
Cutaneous diffuse1
  • Orbital Involvement by Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type. (bvsalud.org)
PMBCL1
  • Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (who.int)
Subcutaneous1
  • A new technique has been presented that results in an acceleration of delayed primary healing with full thickness skin and subcutaneous tissue coverage. (who.int)
Hodgkin's Lymphoma7
Rituximab6
  • This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). (ucsd.edu)
  • Giving atezolizumab, gemcitabine, oxaliplatin, and rituximab may work better in treating patients with transformed diffuse large B-cell lymphoma. (ucsd.edu)
  • This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma . (uci.edu)
  • R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. (uci.edu)
  • Rituximab is a biologic medicine used primarily to treat B-cell lymphoma . (dermnetnz.org)
  • Rituximab has a limited effect on other immune cells. (dermnetnz.org)
Chemotherapy7
  • New review article in Chinese Medical Journal details the potential mechanisms of resistance to the R-CHOP chemotherapy regimen in patients with diffuse large B-cell lymphoma. (news-medical.net)
  • Treatment includes chemotherapy and often stem cell transplantation , either from the patient's own bone marrow (autologous) or sometimes from another person's bone marrow (allogeneic). (dana-farber.org)
  • Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
  • Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (ucsd.edu)
  • He appeared on CNN wearing a head scarf, having lost hair during his chemotherapy treatment for diffuse large B cell lymphoma, a serious but curable form of cancer. (baltimoresun.com)
  • Moreover, 99% of patients had an ECOG performance status of 0, 3% had secondary CNS lymphoma, 67% were refractory to chemotherapy, and 44% had never achieved a CR. (onclive.com)
  • Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. (lu.se)
Autologous2
  • The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
  • Liso-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of CD8+ and CD4+ CAR T cells. (empr.com)
Lymph nodes3
Cases of lymphoma2
  • A review of the literature has identified 11 other cases of lymphoma arising in the context of orthopaedic metallic implants. (karger.com)
  • Most cases of lymphoma are usually considered treatable. (healthline.com)
Patient's1
  • Each dose of the therapy is created using a patient's own T-cells, which are collected and genetically modified to incorporate a gene that targets and eradicates lymphoma cells. (pharmtech.com)
Lymphatic3
  • Lymphoma is a cancer of the lymphatic system , which is part of the body's immune system. (cancercenter.com)
  • These abnormal cells quickly proliferate in the lymphatic system, causing complications. (medicalnewstoday.com)
  • Lymphoma occurs if cancer forms in the lymphatic system. (healthline.com)
Form of extranodal1
  • Regarding primary testicular lymphoma (PTL), it is a rare form of extranodal lymphoma and the most frequent malignant testicular neoplasm in men over the age of 60 years. (intechopen.com)
Cancers1
  • We look forward to the European Commission's decision as we continue to accelerate our research in cell therapy to develop new treatment options for patients living with difficult-to-treat blood cancers. (onclive.com)
Peripheral1
  • Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. (lu.se)
Leukemia2
  • Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. (cdc.gov)
  • Lymphoma Australia is the only incorporated charity in Australia dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma and chronic lymphocytic leukemia (CLL). (lymphoma.org.au)
Systemic3
  • Testicular lymphoma may either represent secondary involvement by systemic disease or primary malignancy. (intechopen.com)
  • PURPOSE: Fluorodeoxyglucose (FDG) uptake of bone marrow (BM) and adipose tissue is known to reflect systemic inflammatory response to cancer cell. (koreamed.org)
  • Because treatment with this therapy can potentially cause severe side effects, FDA's approval carries a boxed warning for cytokine release syndrome (CRS), a systemic response to the activation and proliferation of CAR-T cells that can cause high fever and flu-like symptoms. (pharmtech.com)
Immune system3
  • Autoimmune diseases develop when the immune system mistakenly attacks the body's own healthy cells. (cancercenter.com)
  • This may help the immune system kill cancer cells. (ucsd.edu)
  • This condition is characterized by an excess of immune system cells called B cells (B-cell lymphocytosis), an increased risk of B-cell lymphoma, and susceptibility to infection. (medlineplus.gov)
Bone marrow4
Type4
  • The outlook for this form of cancer depends on the type of diffuse LBCL a person has, the stage that it has progressed to, and whether or not a person receives treatment for it. (medicalnewstoday.com)
  • If this type of lymphoma is completely removed by surgery, no additional treatment may be necessary. (dana-farber.org)
  • The sample may also help your doctor determine the type of lymphoma and how fast it's growing. (healthline.com)
  • What type of lymphoma you have? (lymphoma.org.au)
Testicular1
Therapies2
  • Engineered cell therapies like Yescarta represent the potential for a changing treatment paradigm for cancer patients," said David Chang, MD, PhD, worldwide head of research and development and chief medical officer at Kite, in a company press release. (pharmtech.com)
  • Bristol-Myers Squibb) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies. (empr.com)
Treatment11
  • However, about 40% of the patients either develop resistance to therapy and respond poorly, while a large portion of those who initially respond well to the treatment eventually relapse. (news-medical.net)
  • Diffuse LBCL is an aggressive form of cancer but one that responds well to treatment. (medicalnewstoday.com)
  • According to the American Cancer Society, 3 in 4 people who receive treatment for diffuse LBCL have no further signs of the disease afterward. (medicalnewstoday.com)
  • You must have had two failed modes of treatment or relapses, before being considered for CAR-T cell Immunotherapy, however. (cancer.org)
  • Due to its rare occurrence, the optimal treatment for primary NHL of bone is not known. (medscape.com)
  • The modified T-cells are infused back into the patient for treatment. (pharmtech.com)
  • The primary end point included treatment-related adverse events, dose-limiting toxicities and objective response rate. (empr.com)
  • Primary purpose: Treatment. (who.int)
  • Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. (lu.se)
  • Multimodal deep learning model on interim [F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma. (cdc.gov)
  • CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma. (cdc.gov)
Highly aggressive1
  • All the alterations observed in this specimen occurred simultaneously, pointing to an extensive mechanism that drives rapid genetic diversity in this highly aggressive CNS lymphoma. (fortuneonline.org)